In May, the ACR released a new treatment guideline for the management of gout for simultaneous publication in Arthritis & Rheumatology and Arthritis Care & Research.1 Based on evidence from more than 130 published studies, the guideline makes a total of 42 recommendations—of which 16 are strong: It has 27 recommendations for urate-lowering therapy (ULT)…
ATLANTA—At the ACR/ARP 2019 Annual Meeting, several widely renowned experts across an array of specialty subjects provided a comprehensive and compelling review of advances in the understanding, diagnosis and treatment of a number of rheumatologic conditions. Sjögren’s Syndrome Frederick Vivino, MD, FACR, chief of rheumatology at Penn Presbyterian Medical Center and professor of clinical medicine…
Recent research assessed the risk of gout in patients with type 2 diabetes mellitus prescribed sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with those prescribed a glucagon-like peptide-1 (GLP-1) agonist. The study found patients on the SGLT2 inhibitor had a lower rate of gout, suggesting SGLT2 inhibitors may actually reduce the risk of gout among this patient population…
Patients with uncontrolled gout may benefit from a combination of pegloticase and methotrexate therapy, according to a small, retrospective study…
Monosodium urate (MSU) crystal formation, deposition and gout flares frequently affect joints that have been damaged or are affected by osteoarthritis. These researchers examined the effects of human cartilage homogenates on MSU crystallization and MSU crystal-induced inflammation…
ATLANTA—The authors of the new draft ACR treatment guideline for the management of gout presented the draft guideline on Nov. 13 at the 2019 ACR/ARP Annual Meeting. Based on evidence from more than 130 published studies, there are 42 recommendations, of which 16 were strong, including 27 for urate-lowering therapy (ULT) management, 13 of which…
Case Presentation A 45-year-old man with crystal-proven gout, poorly controlled diabetes and chronic kidney disease was lost to follow-up for six years and presented back to the VA clinic in the midst of a gout flare. He stated he had continued taking 100 mg of allopurinol daily, but his serum urate level was 13.8 mg/dL….
A recent study advances the understanding of factors associated with a target serum urate level of 6 mg/dL or less. Researchers found such factors as having a rheumatologist as the main provider of gout care contributed to achieving and maintaining this outcome. However, the presence of co-morbidities lowered a patient’s chances for achieving the target serum urate level, even with allopurinol use…
Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.